Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytosorbents Corporation on March 31, 2011. The report discloses a significant regulatory milestone for the Company's flagship product, CytoSorb®.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure and does not contain financial statements or pro forma information.
Material Changes
The primary material event reported is the achievement of European CE Mark approval for CytoSorb®. The product is approved as an extracorporeal cytokine filter for use in situations where excessive cytokine levels exist.
Outlook and Management Commentary
Management issued a press release (Exhibit 99.1) to announce the CE Mark approval. The filing notes that the information contained in the press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific scope and limitations of the European CE Mark approval for CytoSorb® as detailed in the attached press release.
- Confirm the timeline for commercial availability of the product in European markets following this approval.
- Review subsequent filings for any financial impact or revenue recognition related to this regulatory milestone.